nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB10—female reproductive system—vaginal cancer	0.0356	0.0495	CbGeAlD
Carfilzomib—PSMB10—female gonad—vaginal cancer	0.0324	0.045	CbGeAlD
Carfilzomib—PSMB8—uterine cervix—vaginal cancer	0.0306	0.0426	CbGeAlD
Carfilzomib—PSMB8—urethra—vaginal cancer	0.0281	0.0391	CbGeAlD
Carfilzomib—PSMB8—endometrium—vaginal cancer	0.0277	0.0385	CbGeAlD
Carfilzomib—PSMB5—uterine cervix—vaginal cancer	0.0271	0.0376	CbGeAlD
Carfilzomib—PSMB8—mammalian vulva—vaginal cancer	0.0268	0.0372	CbGeAlD
Carfilzomib—PSMB5—urethra—vaginal cancer	0.0249	0.0346	CbGeAlD
Carfilzomib—PSMB5—endometrium—vaginal cancer	0.0245	0.034	CbGeAlD
Carfilzomib—PSMB5—mammalian vulva—vaginal cancer	0.0237	0.0329	CbGeAlD
Carfilzomib—PSMB1—uterine cervix—vaginal cancer	0.0236	0.0329	CbGeAlD
Carfilzomib—PSMB2—uterine cervix—vaginal cancer	0.0231	0.0321	CbGeAlD
Carfilzomib—PSMB5—uterus—vaginal cancer	0.0225	0.0313	CbGeAlD
Carfilzomib—PSMB1—urethra—vaginal cancer	0.0217	0.0302	CbGeAlD
Carfilzomib—PSMB1—endometrium—vaginal cancer	0.0214	0.0297	CbGeAlD
Carfilzomib—PSMB2—urethra—vaginal cancer	0.0212	0.0295	CbGeAlD
Carfilzomib—PSMB8—female gonad—vaginal cancer	0.0209	0.029	CbGeAlD
Carfilzomib—PSMB2—endometrium—vaginal cancer	0.0209	0.029	CbGeAlD
Carfilzomib—PSMB8—vagina—vaginal cancer	0.0208	0.0288	CbGeAlD
Carfilzomib—PSMB1—mammalian vulva—vaginal cancer	0.0207	0.0288	CbGeAlD
Carfilzomib—PSMB2—mammalian vulva—vaginal cancer	0.0202	0.0281	CbGeAlD
Carfilzomib—PSMB1—uterus—vaginal cancer	0.0197	0.0274	CbGeAlD
Carfilzomib—PSMB2—uterus—vaginal cancer	0.0192	0.0267	CbGeAlD
Carfilzomib—PSMB5—female gonad—vaginal cancer	0.0184	0.0256	CbGeAlD
Carfilzomib—PSMB5—vagina—vaginal cancer	0.0183	0.0255	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—vaginal cancer	0.0177	0.0246	CbGeAlD
Carfilzomib—PSMB10—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0177	0.0631	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0176	0.0628	CbGpPWpGaD
Carfilzomib—PSMB2—female reproductive system—vaginal cancer	0.0173	0.024	CbGeAlD
Carfilzomib—PSMB8—Interferon Signaling—EIF4A3—vaginal cancer	0.0163	0.058	CbGpPWpGaD
Carfilzomib—PSMB1—female gonad—vaginal cancer	0.0161	0.0224	CbGeAlD
Carfilzomib—PSMB1—vagina—vaginal cancer	0.016	0.0223	CbGeAlD
Carfilzomib—PSMB2—female gonad—vaginal cancer	0.0157	0.0219	CbGeAlD
Carfilzomib—PSMB2—vagina—vaginal cancer	0.0156	0.0217	CbGeAlD
Carfilzomib—PSMB10—Metabolism of RNA—EIF4A3—vaginal cancer	0.0151	0.054	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism of RNA—EIF4A3—vaginal cancer	0.0151	0.0537	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0134	0.0478	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0134	0.0478	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0134	0.0478	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism of mRNA—EIF4A3—vaginal cancer	0.0132	0.0471	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon alpha/beta signaling—IFNA1—vaginal cancer	0.0131	0.0466	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism of RNA—EIF4A3—vaginal cancer	0.0115	0.0409	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism of RNA—EIF4A3—vaginal cancer	0.0115	0.0409	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism of RNA—EIF4A3—vaginal cancer	0.0115	0.0409	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism of RNA—EIF4A3—vaginal cancer	0.0113	0.0403	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.0109	0.0387	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon Signaling—IFNA1—vaginal cancer	0.00608	0.0217	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EIF4A3—vaginal cancer	0.00475	0.0169	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EIF4A3—vaginal cancer	0.00473	0.0168	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—EIF4A3—vaginal cancer	0.00472	0.0168	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—EIF4A3—vaginal cancer	0.0047	0.0167	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00406	0.0145	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EIF4A3—vaginal cancer	0.0036	0.0128	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EIF4A3—vaginal cancer	0.0036	0.0128	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EIF4A3—vaginal cancer	0.0036	0.0128	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—EIF4A3—vaginal cancer	0.00358	0.0128	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—EIF4A3—vaginal cancer	0.00358	0.0128	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—EIF4A3—vaginal cancer	0.00358	0.0128	CbGpPWpGaD
Carfilzomib—ABCB1—epithelium—vaginal cancer	0.00355	0.00494	CbGeAlD
Carfilzomib—PSMB8—Immune System—EIF4A3—vaginal cancer	0.00355	0.0126	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—EIF4A3—vaginal cancer	0.00353	0.0126	CbGpPWpGaD
Carfilzomib—ABCB1—uterine cervix—vaginal cancer	0.00352	0.0049	CbGeAlD
Carfilzomib—ABCB1—urethra—vaginal cancer	0.00324	0.0045	CbGeAlD
Carfilzomib—ABCB1—endometrium—vaginal cancer	0.00319	0.00443	CbGeAlD
Carfilzomib—ABCB1—mammalian vulva—vaginal cancer	0.00308	0.00429	CbGeAlD
Carfilzomib—ABCB1—uterus—vaginal cancer	0.00294	0.00408	CbGeAlD
Carfilzomib—ABCB1—female reproductive system—vaginal cancer	0.00264	0.00367	CbGeAlD
Carfilzomib—ABCB1—female gonad—vaginal cancer	0.0024	0.00334	CbGeAlD
Carfilzomib—ABCB1—vagina—vaginal cancer	0.00239	0.00332	CbGeAlD
Carfilzomib—PSMB10—Immune System—IFNA1—vaginal cancer	0.00178	0.00633	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IFNA1—vaginal cancer	0.00177	0.0063	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.00168	0.00598	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL2—vaginal cancer	0.00138	0.00491	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IFNA1—vaginal cancer	0.00135	0.00479	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IFNA1—vaginal cancer	0.00135	0.00479	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IFNA1—vaginal cancer	0.00135	0.00479	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IFNA1—vaginal cancer	0.00133	0.00473	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL2—vaginal cancer	0.000734	0.00262	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL2—vaginal cancer	0.000731	0.0026	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—vaginal cancer	0.000556	0.00198	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—vaginal cancer	0.000556	0.00198	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—vaginal cancer	0.000556	0.00198	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—vaginal cancer	0.000549	0.00195	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—vaginal cancer	0.000475	0.00169	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—vaginal cancer	0.000472	0.00168	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—vaginal cancer	0.00036	0.00128	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—vaginal cancer	0.00036	0.00128	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—vaginal cancer	0.00036	0.00128	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—vaginal cancer	0.000355	0.00126	CbGpPWpGaD
